RU2012116880A - Обработка нерастворимых в воде наночастиц гидрофильными конъюгатами альфа-гидроксифосфоновой кислоты, модифицированные таким образом наночастицы и их применение в качестве контрастных агентов - Google Patents
Обработка нерастворимых в воде наночастиц гидрофильными конъюгатами альфа-гидроксифосфоновой кислоты, модифицированные таким образом наночастицы и их применение в качестве контрастных агентов Download PDFInfo
- Publication number
- RU2012116880A RU2012116880A RU2012116880/15A RU2012116880A RU2012116880A RU 2012116880 A RU2012116880 A RU 2012116880A RU 2012116880/15 A RU2012116880/15 A RU 2012116880/15A RU 2012116880 A RU2012116880 A RU 2012116880A RU 2012116880 A RU2012116880 A RU 2012116880A
- Authority
- RU
- Russia
- Prior art keywords
- alpha
- ethylene oxide
- nanoparticle
- hydroxyphosphonate
- nanoparticles
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract 18
- 239000002872 contrast media Substances 0.000 title claims abstract 4
- 239000002253 acid Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 12
- 229920000642 polymer Polymers 0.000 claims abstract 12
- 238000000034 method Methods 0.000 claims abstract 11
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims abstract 8
- 125000006850 spacer group Chemical group 0.000 claims abstract 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract 4
- 238000002059 diagnostic imaging Methods 0.000 claims abstract 4
- 238000002595 magnetic resonance imaging Methods 0.000 claims abstract 3
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 238000002347 injection Methods 0.000 claims abstract 2
- 239000007924 injection Substances 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Substances 0.000 abstract 1
- 239000002616 MRI contrast agent Substances 0.000 abstract 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
- A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
- A61K49/1842—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a phosphate or a phosphonate, not being a phospholipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
- A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/609,799 US9205155B2 (en) | 2009-10-30 | 2009-10-30 | Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents |
| US12/609,799 | 2009-10-30 | ||
| PCT/EP2010/066429 WO2011051422A2 (en) | 2009-10-30 | 2010-10-29 | Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012116880A true RU2012116880A (ru) | 2013-12-10 |
Family
ID=43480950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012116880/15A RU2012116880A (ru) | 2009-10-30 | 2010-10-29 | Обработка нерастворимых в воде наночастиц гидрофильными конъюгатами альфа-гидроксифосфоновой кислоты, модифицированные таким образом наночастицы и их применение в качестве контрастных агентов |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9205155B2 (https=) |
| EP (1) | EP2493512B1 (https=) |
| JP (1) | JP5997609B2 (https=) |
| KR (1) | KR20120101362A (https=) |
| CN (1) | CN102639153B (https=) |
| AU (1) | AU2010311437A1 (https=) |
| BR (1) | BR112012010113A2 (https=) |
| CA (1) | CA2777871A1 (https=) |
| ES (1) | ES2720152T3 (https=) |
| IN (1) | IN2012DN02804A (https=) |
| MX (1) | MX2012005022A (https=) |
| RU (1) | RU2012116880A (https=) |
| WO (1) | WO2011051422A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767430C2 (ru) * | 2017-06-28 | 2022-03-17 | Рикен | Наночастица, содержащее ее контрастное вещество для магнитно-резонансной томографии и лигандное соединение |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8986836B2 (en) * | 2009-03-19 | 2015-03-24 | Ohio University | Microspheres and their methods of preparation |
| US8920681B2 (en) | 2009-12-30 | 2014-12-30 | Korea University Research And Business Foundation | Electrically conductive polymers with enhanced conductivity |
| US8895068B2 (en) | 2010-12-15 | 2014-11-25 | General Electric Company | Nanoparticle composition and associated methods thereof |
| CA2819795A1 (en) * | 2010-12-15 | 2012-06-21 | General Electric Company | Nanoparticle composition and associated methods thereof |
| US8889103B2 (en) | 2010-12-15 | 2014-11-18 | General Electric Company | Diagnostic agent composition and associated methods thereof |
| US9474810B2 (en) * | 2012-03-02 | 2016-10-25 | General Electric Company | Superparamagnetic nanoparticles with PEG substituted α-hydroxy phosphonate shells |
| US9251937B2 (en) * | 2012-06-29 | 2016-02-02 | General Electric Company | Heat stable nanoparticle preparations and associated methods thereof |
| US20190001001A1 (en) * | 2017-07-03 | 2019-01-03 | General Electric Company | Drug design for application-dependent payload, controlled pharmacokinetic distribution, and renal clearance |
| WO2019067580A1 (en) * | 2017-09-26 | 2019-04-04 | The Board Of Trustees Of The University Of Arkansas | ZERO-VALENT IRON COMPOSITE NANOPARTICLES AND THEIR APPLICATIONS |
| CN110734460B (zh) * | 2019-10-22 | 2022-03-29 | 华南师范大学 | 一类磺酸-膦酸配体的制备及其用途 |
| CN118748269B (zh) * | 2024-08-05 | 2025-10-31 | 瑞固(衢州)新材料科技有限公司 | 一种硫化物固态电解质及其制备方法与电池 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5651493A (en) | 1979-10-02 | 1981-05-09 | Yoshitomi Pharmaceut Ind Ltd | Diphosphoglycerol and its preparation |
| JPS6043217A (ja) | 1983-08-19 | 1985-03-07 | Toshiba Corp | 磁気記録媒体 |
| DE3343586A1 (de) | 1983-11-29 | 1985-06-05 | Herbert Dr. 1000 Berlin Pilgrimm | Verfahren zur entkeimung eines mediums und vorrichtung zur durchfuehrung |
| DE3440190A1 (de) | 1984-11-01 | 1986-05-15 | Michel-Kim, Herwig, 1000 Berlin | Verfahren und vorrichtung zur erzeugung von stickstoffduenger und stickstoffangereicherter biomasse aus luft |
| DE3443810A1 (de) | 1984-11-28 | 1986-05-28 | Herbert Dr. 1000 Berlin Pilgrimm | Verfahren zur entkeimung eines mediums |
| DE3624626A1 (de) | 1986-07-18 | 1988-01-28 | Pilgrimm Herbert | Verfahren zur abtrennung von stoffen aus einem stoffgemisch unter verwendung von magnetischen fluessigkeiten |
| DE3709851A1 (de) * | 1987-03-24 | 1988-10-06 | Silica Gel Gmbh Adsorptions Te | Nmr-diagnostische fluessigkeitszusammensetzungen |
| DE3709852A1 (de) | 1987-03-24 | 1988-10-06 | Silica Gel Gmbh Adsorptions Te | Stabile magnetische fluessigkeitszusammensetzungen und verfahren zu ihrer herstellung und ihre verwendung |
| DE4309333A1 (de) | 1993-03-17 | 1994-09-22 | Silica Gel Gmbh | Superparamagnetische Teilchen, Verfahren zu ihrer Herstellung und Verwendung derselben |
| DE59403734D1 (de) * | 1993-03-17 | 1997-09-18 | Silica Gel Gmbh | Superparamagnetische teilchen, verfahren zu ihrer herstellung und verwendung derselben |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| ATE191086T1 (de) * | 1994-07-27 | 2000-04-15 | Pilgrimm Herbert | Superparamagnetische teilchen, verfahren zur herstellung und deren verwendung |
| DE19612001A1 (de) * | 1996-03-18 | 1997-09-25 | Silica Gel Gmbh Adsorptions Te | Superparamagnetische Teilchen mit vergrößerter R¶1¶-Relaxivität, Verfahren zur Herstellung und deren Verwendung |
| DE19726282A1 (de) | 1997-06-20 | 1998-12-24 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern |
| DE10016559A1 (de) | 2000-04-03 | 2001-10-18 | Eucro Europe Contract Res Gmbh | System für den Transport von Aktivstoffen in einem biologischen System |
| ATE472511T1 (de) | 2001-08-16 | 2010-07-15 | Essilor Int | Verfahren zur herstellung stabiler dispersionen metallischer nanopartikel, stabile dispersion hergestellt auf basis dieses verfahrens und beschichtungszusammensetzungen enthaltend diese dispersionen |
| DE10222481A1 (de) * | 2002-05-22 | 2003-12-04 | Eucro Europe Contract Res Gmbh | Kontrastmittel für die Verwendung in bildgebenden Verfahren |
| US6797380B2 (en) | 2002-07-31 | 2004-09-28 | General Electric Company | Nanoparticle having an inorganic core |
| DE50213399D1 (de) * | 2002-10-09 | 2009-05-07 | Pilgrimm Helga | Stabilisierte superparamagnetische teilchen |
| US7560160B2 (en) * | 2002-11-25 | 2009-07-14 | Materials Modification, Inc. | Multifunctional particulate material, fluid, and composition |
| FR2848850B1 (fr) * | 2002-12-20 | 2005-06-24 | Guerbet Sa | Nouvelles compositions de particules magnetiques recouvertes de derives gem-bisphosphonates. |
| US20040161435A1 (en) | 2003-02-14 | 2004-08-19 | Gupta Shyam K. | Skin Firming Anti-Aging Cosmetic Mask Compositions |
| DE10323816A1 (de) * | 2003-05-23 | 2004-12-09 | Basf Ag | Verfahren zur Herstellung von Mischoxiden mit mittleren Durchmessern kleiner als 10 Nanometer |
| US20060018835A1 (en) * | 2004-04-02 | 2006-01-26 | General Electric Company | Nanoparticles with inorganic core and methods of using them |
| CN100334166C (zh) | 2005-01-26 | 2007-08-29 | 上海大学 | 一种纳米碳酸钙的改性方法 |
| US8084275B2 (en) * | 2005-02-08 | 2011-12-27 | Fujifilm Corporation | Magnetic composite body, production method thereof, method for removing substance with mannose on its surface, and method for concentrating substance with mannose on its surface |
| KR100746312B1 (ko) * | 2005-03-14 | 2007-08-03 | 한국화학연구원 | 수용성 산화철 나노 입자 및 이의 제조방법 |
| CN101687385A (zh) | 2005-05-12 | 2010-03-31 | 佐治亚科技研究公司 | 包覆的金属氧化物纳米颗粒及其制备方法 |
| US7767736B2 (en) | 2005-12-05 | 2010-08-03 | 3M Innovative Properties Company | Flame retardant polymer composition |
| DE102005059751A1 (de) | 2005-12-09 | 2007-06-14 | Ferropharm Gmbh Forschungslabor | Wässrige Dispersion von superparamagnetischen Eindomänenteilchen, deren Herstellung und Verwendung zur Diagnose und Therapie |
| ITFI20060006A1 (it) | 2006-01-04 | 2007-07-05 | Colorobbia Italiana Spa | Nanoparticelle funzionalizzate, loro produzione ed uso |
| DE102006007888A1 (de) | 2006-02-21 | 2007-08-23 | Degussa Gmbh | Aluminiumoxid enthaltende Dispersion, Zubereitung enthaltend diese Dispersion und ein Melaminharz und mittels dieser Zubereitung hergestelles gehärtetes Produkt |
| JP5282031B2 (ja) | 2006-05-15 | 2013-09-04 | ドミトリィ ビー カーポティン | 有機物を含む磁性微粒子 |
| FR2904784B1 (fr) * | 2006-08-10 | 2010-09-03 | Surfactis Technologies | Procede de recouvrement de surfaces metalliques et minerales par de monocouches autoassemblees de composes bisphosphoniques et leurs utilisations |
| US20080299046A1 (en) | 2006-10-16 | 2008-12-04 | The Trustees Of Columbia University In The City Of New York | Methods for controlling surface functionality of metal oxide nanoparticles, metal oxide nanoparticles having controlled functionality, and uses thereof |
| EP2152320A2 (en) | 2007-04-30 | 2010-02-17 | Intezyne Technologies Incorporated | Encapsulated contrast agents |
| US9072789B2 (en) | 2007-07-20 | 2015-07-07 | The Trustees Of Princeton University | Nano-particle surface modification |
| SG150405A1 (en) | 2007-08-29 | 2009-03-30 | Agency Science Tech & Res | Method of coating a particle |
| FR2921838A1 (fr) * | 2007-10-05 | 2009-04-10 | Guerbet Sa | Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile |
| KR20090038337A (ko) | 2007-10-15 | 2009-04-20 | 재단법인서울대학교산학협력재단 | 무기계 나노입자를 수계 매질에 분산시키는 생체적합성분산 안정화제 |
| KR20100107008A (ko) | 2007-12-13 | 2010-10-04 | 아두로 바이오테크 | 리간드 접합 온열요법 서셉터 및 이의 제조 방법 |
| US20090226376A1 (en) * | 2008-03-05 | 2009-09-10 | General Electric Company | Novel Mixed Ligand Core/Shell Iron Oxide Nanoparticles for Inflammation Imaging |
| US8173198B2 (en) | 2008-07-23 | 2012-05-08 | Life Technologies Corporation | Deposition of metal oxides onto surfaces as an immobilization vehicle for carboxylated or phophated particles or polymers |
| US20100166664A1 (en) | 2008-12-29 | 2010-07-01 | General Electric Company | Nanoparticle contrast agents for diagnostic imaging |
-
2009
- 2009-10-30 US US12/609,799 patent/US9205155B2/en active Active
-
2010
- 2010-10-29 MX MX2012005022A patent/MX2012005022A/es not_active Application Discontinuation
- 2010-10-29 AU AU2010311437A patent/AU2010311437A1/en not_active Abandoned
- 2010-10-29 JP JP2012535840A patent/JP5997609B2/ja active Active
- 2010-10-29 CN CN201080049469.4A patent/CN102639153B/zh active Active
- 2010-10-29 RU RU2012116880/15A patent/RU2012116880A/ru not_active Application Discontinuation
- 2010-10-29 WO PCT/EP2010/066429 patent/WO2011051422A2/en not_active Ceased
- 2010-10-29 BR BR112012010113A patent/BR112012010113A2/pt not_active IP Right Cessation
- 2010-10-29 CA CA2777871A patent/CA2777871A1/en not_active Abandoned
- 2010-10-29 IN IN2804DEN2012 patent/IN2012DN02804A/en unknown
- 2010-10-29 ES ES10771742T patent/ES2720152T3/es active Active
- 2010-10-29 EP EP10771742.3A patent/EP2493512B1/en active Active
- 2010-10-29 KR KR1020127010759A patent/KR20120101362A/ko not_active Withdrawn
-
2015
- 2015-10-21 US US14/919,077 patent/US9827335B2/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767430C2 (ru) * | 2017-06-28 | 2022-03-17 | Рикен | Наночастица, содержащее ее контрастное вещество для магнитно-резонансной томографии и лигандное соединение |
| US11389550B2 (en) | 2017-06-28 | 2022-07-19 | Riken | Nanoparticle, contrast agent for magnetic resonance imaging containing same, and ligand compound |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102639153B (zh) | 2017-02-22 |
| IN2012DN02804A (https=) | 2015-07-24 |
| WO2011051422A3 (en) | 2011-07-21 |
| EP2493512B1 (en) | 2019-01-23 |
| BR112012010113A2 (pt) | 2019-09-24 |
| MX2012005022A (es) | 2012-06-08 |
| WO2011051422A2 (en) | 2011-05-05 |
| AU2010311437A1 (en) | 2012-04-12 |
| CA2777871A1 (en) | 2011-05-05 |
| CN102639153A (zh) | 2012-08-15 |
| US9827335B2 (en) | 2017-11-28 |
| ES2720152T3 (es) | 2019-07-18 |
| JP5997609B2 (ja) | 2016-09-28 |
| US20160038617A1 (en) | 2016-02-11 |
| KR20120101362A (ko) | 2012-09-13 |
| US20110104072A1 (en) | 2011-05-05 |
| JP2013509381A (ja) | 2013-03-14 |
| US9205155B2 (en) | 2015-12-08 |
| EP2493512A2 (en) | 2012-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012116880A (ru) | Обработка нерастворимых в воде наночастиц гидрофильными конъюгатами альфа-гидроксифосфоновой кислоты, модифицированные таким образом наночастицы и их применение в качестве контрастных агентов | |
| Kim et al. | A cancer-recognizable MRI contrast agents using pH-responsive polymeric micelle | |
| Zhang et al. | Integrating fluorinated polymer and manganese‐layered double hydroxide nanoparticles as pH‐activated 19F MRI agents for specific and sensitive detection of breast cancer | |
| Park et al. | Multi-modal transfection agent based on monodisperse magnetic nanoparticles for stem cell gene delivery and tracking | |
| Lin et al. | Carboxymethyl chitosan-assisted MnOx nanoparticles: Synthesis, characterization, detection and cartilage repair in early osteoarthritis | |
| Hao et al. | Multifunctional nanosheets based on folic acid modified manganese oxide for tumor-targeting theranostic application | |
| Wang et al. | Antifouling manganese oxide nanoparticles: synthesis, characterization, and applications for enhanced MR imaging of tumors | |
| ES2787502T3 (es) | Polímero biocompatible y nanopartícula magnética con biocompatibilidad | |
| EP2322227A1 (en) | Ph-sensitive dendritic polymeric micelles | |
| JP2013509381A5 (https=) | ||
| CN101390826B (zh) | 一种磁性肿瘤靶向聚合物纳米囊泡及其制备方法 | |
| CN105194689A (zh) | 一种基于siRNA的双偶联复合物 | |
| CN104399092A (zh) | 一种rgd修饰的超小型超顺磁氧化铁纳米颗粒的制备方法 | |
| ES2718424T3 (es) | Un procedimiento para preparar nanopartículas poliméricas monocatenarias dispersables en agua | |
| CN104784711B (zh) | 透明质酸稳定的高弛豫率氧化钆磁共振纳米探针 | |
| Gharehaghaji et al. | PEGylated Magnetite/Hydroxyapatite: A Green Nanocomposite for T2‐Weighted MRI and Curcumin Carrying | |
| Wu et al. | Multifunctional nanostructures for tumor-targeted molecular imaging and photodynamic therapy | |
| Jiang et al. | Carbon quantum dots carrying antibiotics for treating dental implant bacterial infections following photothermal therapy | |
| Wang et al. | Insights into Non‐Metallic Magnetic Resonance Imaging Contrast Agents: Advances and Perspectives | |
| Zhang et al. | Functionalized magnetic nanochains with enhanced MR imaging: a novel nanosystem for targeting and inhibition of early glioma | |
| Zhang et al. | Lactose-modified enzyme-sensitive branched polymers as a nanoscale liver cancer-targeting MRI contrast agent | |
| CN106178004A (zh) | 一种磁性纳米诊疗剂及其制备方法和应用 | |
| CN113616815A (zh) | pH响应的T1/T2切换型MRI造影剂及其制备方法与应用 | |
| CN103432585A (zh) | 叶酸受体α亚型高效介导的靶向标记系统 | |
| CN106310297B (zh) | 多功能高分子前药纳米递药系统及制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20160627 |